TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00537836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 86-5310 (ZK 283197)
Description: 3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 86-5310 (ZK 283197)
Description: 3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily p.o. over 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17ß-estradiol
Description: 1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
Study: NCT01975441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 6mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 6mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 6mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 200 mcg/kg
Study: NCT02196129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinbaro-3
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hwangryun
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Study: NCT00745602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-invasive testing
Description: non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
Study: NCT03036943

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluciclovine
Description: Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer
Study: NCT01530919

Intervention type: PROCEDURE
Intervention: Minimally invasive radioguided parathyroidectomy
Description: After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
Study: NCT01928849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cherry Syrup
Description: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
Study: NCT01934179

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo blood sample collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02065557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT01799694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inject of Autologous Adipose-derived stem cells
Description: Inject in muscle of autologous adipose derived stem cells
Study: NCT03025204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Proteins
Description: EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Proteins
Description: EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement
Description: After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
Study: NCT06135038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve block with physical therapy
Description: Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 Physical therapy
Description: A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.
Study: NCT02760303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
Study: NCT02572154

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and sperm samples
Description: 20 ml of blood and sperm samples for sperm DNA fragmentation exploration

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and sperm samples
Description: 20 ml of blood and sperm samples for sperm DNA fragmentation exploration
Study: NCT03613870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PermeaDerm
Description: Wound treatment with PermeaDerm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Wound treatment with Mepilex Ag
Study: NCT03323762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC)
Description: The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
Study: NCT01116531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
Study: NCT03823625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Description: Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy plus Nivolumab
Description: Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days.
Study: NCT01462942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Inhaled Aclidinium 400 μg, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol 12 μg, twice per day
Study: NCT04510168

Intervention type: DRUG
Intervention: 11C-ER176
Description: PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)

Intervention type: DRUG
Intervention: [F-18]MK-6240
Description: PET imaging to measure tau; target imaging dose of 4 to 5 mCi

Intervention type: DRUG
Intervention: Florbetaben
Description: PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Brain MRI

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Brain MRI
Study: NCT03565289

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: During a routine blood draw an additional tube of blood will be taken for the study.
Study: NCT02246777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex-PRESS® Glaucoma Filtration Device, Model P50PL
Study: NCT03644732

Intervention type: PROCEDURE
Intervention: SEEG Group
Description: Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
Study: NCT01027845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa
Description: Subcutaneous injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa
Description: Subcutaneous injection, 4 doses
Study: NCT03749200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obemat2.0 therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular practise in primary care
Study: NCT02022917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
Study: NCT02420574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole BENDEX
Description: randomized clinical trial with 2 parallel arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole OVIS
Study: NCT00909974

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: UNIMMAP - multiple micronutrients
Description: Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement enriched with multiple micronutrients
Description: One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
Study: NCT03742596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Capsule
Description: The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
Study: NCT04008706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
Study: NCT03742596

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: The Placebos will be coded in a specific label by a researcher.
Study: NCT01189266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03336346

Intervention type: DRUG
Intervention: dolutegravir
Description: HIV integrase strand transfer inhibitor used in combination ART

Intervention type: DEVICE
Intervention: ENG implant
Description: Reversible contraception implant

Intervention type: DEVICE
Intervention: ENG implant
Description: Reversible contraception implant

Intervention type: DEVICE
Intervention: ENG implant
Description: Reversible contraception implant

Intervention type: DRUG
Intervention: Efavirenz
Description: non-nucleoside reverse transcriptase inhibitor used in combination ART
Study: NCT01298258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150mg
Study: NCT03147963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given until progression or patient intolerance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be given until progression or patient intolerance
Study: NCT02551146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A Locator with retention elements
Description: Insertion of GC Pilier locator abutments with retention elements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B Locator without retention elements
Description: Insertion of GC Pilier locator abutments without retention elements